Following the recent approval of REDEMPLO ® for the treatment of patients with familial chylomicronemia syndrome (FCS), Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is now a commercial-stage company ...

Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. The company could report readouts from its drugs in three indications in H1 2026: casdozokitug in ...

Earnings Call Insights: Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 CEO Robert Barrow stated, "We delivered another solid quarter, advancing our clinical programs and continuing to build one of the ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones include seven ...

Paul L. Berns, Chief Executive Officer, stated that Neumora "prioritized obesity as the lead indication for NMRA-215, our highly brain-penetrant NLRP3 inhibitor." He outlined, "We expect to have up to ...

(RTTNews) - The eyes are often called the windows to the soul, but they also reflect our overall health. One of the most important parts of our eyes is the retina, a layer of cells at the back of the ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price ...